SIETES :: 93212 citas

Resultados de la búsqueda por INCRETINAS REFINAR BÚSQUEDA

1.

Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]

2.

Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JPW, Vestergaard P, Henry RMA. The use of incretins and fractures – A meta-analysis on population-based real life data. Br J Clin Pharmacol 2017;83:923-6. [Ref.ID 101971]

3.

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]

4.

Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]

5.

Ariz MJ, Elizondo G. Nuevos antidiabéticos. ¿Qué lugar deben ocupar en terapéutica?. Boletín de Información Farmacoterapéutica de Navarra 2016;24:. [Ref.ID 101436]

6.

Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 2016;354:i3477. [Ref.ID 100598]

7.

McGuire H, Longson D, Adler A, Farmer A, Lewin I, on behalf of the Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ 2016;353:i1575. [Ref.ID 100303]

8.

Mascolo A, Rafaniello C, Sportiello L, Sessa M, Cimmaruta D, Rossi F, Capuano A. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf 2016;39:401-7. [Ref.ID 100253]

9.

Maruthur NM. Diabetes Medications as Monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2016:1. [Ref.ID 100148]

10.

Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ 2016;352:i1450. [Ref.ID 100144]

11.

Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P, for the CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145-54. [Ref.ID 100077]

12.

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ 2016;352:i581. [Ref.ID 100066]

13.

Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]

14.

Anónimo. Nuevos hipoglucemiantes: sin noticias de eficacia y nuevos efectos adversos. Butlletí Groc 2015;28:11-4. [Ref.ID 99840]

15.

Anónimo. Gliptines, exénatide, liraglutide: "obstructions intestinales". Prescrire 2015;35:665. [Ref.ID 99714]

16.

Puig-Domingo M, Pellitero S. Nuevos agentes terapéuticos para la diabetes tipo 2. Med Clin (Barc) 2015;144:560-5. [Ref.ID 99167]

17.

Fernández-Balsells M, Ricart-Engel W. Nous tractaments farmacològics par a la diabetis tipus 2: els agents incretínics i els agents glucosúrics. Butlletí d'Informació Terapèutica 2015;26:1-8. [Ref.ID 98957]

18.

Fernández-Balsells M, Ricart-Engel W. Nous tractaments farmacològis per a la diabetis mellitus tipus 2: els agents incretínics i els agents glucosúrics. Butlletí d'Informació Terapèutica 2015;26:1-9. [Ref.ID 98853]

19.

Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228-34. [Ref.ID 98434]

20.

Anónimo. Lixisenatida en el tractament de la diabetis mellitus tipus 2 en combinació amb altres hipoglucemiants i/o insulina basa. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) 2014:agosto. [Ref.ID 98419]